Notice type: 3rd Party Publications
Date: 28/07/2014
Important Safety Information communication from GlaxoSmithKline Pharmaceuticals reminding of risk of serious and fatal infusion reactions associated with Arzerra (ofatumumab).
Important Safety Information - Arzerra (ofatumumab)